BMS-936559

BIOLOGICAL2 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), Bristol-Myers Squibb

Conditions

HIV InfectionsSeptic ShockSevere Sepsis

Phase 1

Safety and Immune Response of BMS-936559 in HIV-Infected People Taking Combination Antiretroviral Therapy

CompletedNCT02028403

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

Start: 2014-06-30End: 2015-11-30Updated: 2021-11-05

Safety, Pharmacokinetics and Pharmacodynamics of BMS-936559 in Severe Sepsis

TerminatedNCT02576457

Bristol-Myers SquibbSeptic Shock, Severe Sepsis

Start: 2015-12-02End: 2017-03-15Updated: 2017-09-15

Related Papers

Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1 Infected Participants on Suppressive Antiretroviral Therapy

The Journal of Infectious Diseases2017-04-17219 citations